Evidence map›Paper›PMID 42428031›Full record

ArticleIJU case reports2026

Metastatic Testicular Germ Cell Tumor in a Patient With Neurofibromatosis Type 1: Treatment With Trametinib Based on

Keita Goto, Toshiki Kijima, Yusuke Sato, Kousuke Watanabe, Hidenori Kage, Katsutoshi Oda, Tatsunori Shimoi, Kazuyuki Ishida, Haruki Kume, Takao Kamai

Abstract read
In one paragraph

Article in IJU case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Keita GotoDepartment of Urology Dokkyo Medical University Mibu Japan.
Toshiki KijimaDepartment of Urology Dokkyo Medical University Mibu Japan.ORCID https://orcid.org/0000-0002-4380-9294
Yusuke SatoDepartment of Urology, Graduate School of Medicine The University of Tokyo Tokyo Japan.ORCID https://orcid.org/0000-0002-6239-6050
Kousuke WatanabeNext-Generation Precision Medicine Development Laboratory, Graduate School of Medicine The University of Tokyo Tokyo Japan.ORCID https://orcid.org/0000-0003-4670-3679
Hidenori KageDepartment of Respiratory Medicine, Graduate School of Medicine The University of Tokyo Tokyo Japan.ORCID https://orcid.org/0000-0003-3658-4442
Katsutoshi OdaDivision of Integrative Genomics, Graduate School of Medicine The University of Tokyo Tokyo Japan.
Tatsunori ShimoiDepartment of Medical Oncology National Cancer Center Hospital Tokyo Japan.
Kazuyuki IshidaDepartment of Diagnostic Pathology Dokkyo Medical University Mibu Japan.ORCID https://orcid.org/0000-0002-2804-4588
Haruki KumeDepartment of Urology, Graduate School of Medicine The University of Tokyo Tokyo Japan.
Takao KamaiDepartment of Urology Dokkyo Medical University Mibu Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Neurofibromatosis type 1 (NF1) is a genetic disorder that increases the risk of various tumors. However, its association with testicular germ cell tumors (GCTs) is rare. We report a case of metastatic GCT in an NF1 patient treated with precision medicine. Case Presentation: A 40-year-old male with NF1 presented with a left testicular non-seminomatous GCT and lung metastases. The tumor showed progressive disease after chemotherapy (VIP, TGP) and surgical removal of metastases. Comprehensive genomic profiling (CGP) test found a pathogenic Conclusion: This is the first report of trametinib for a metastatic GCT with an Trial Registration: The prospective trial of patient-proposed healthcare services with multiple targeted agents based on the results of gene profiling by multigene panel test (BELIEVE), NCCH1901/jRCTs031190104.

Indexed as

MEK inhibitorneurofibromatosis type 1precision medicinetesticular germ cell tumortrametinib

Identifiers

PMID42428031
PMCPMC13349590

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.